Famotidine interactions
Full monograph for FamotidineCheck it against another medicine
Medicines
677 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Dasatinib | Major | Absorption | Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, long-term suppression of gastric acid secretion by H2-receptor… | 4 sources — open the full entry |
| Neratinib Maleate | Major | Absorption | Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of neratinib. The solubility of… | 5 sources — open the full entry |
| Pazopanib Hydrochloride | Major | Absorption | Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of pazopanib and reduce its… | 7 sources — open the full entry |
| Selpercatinib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in… | 2 sources — open the full entry |
| Sotorasib | Major | Absorption | Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of sotorasib and reduce its concentrations in plasma. | 2 sources — open the full entry |
| Tizanidine Hydrochloride | Major | Metabolism | Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations and pharmacologic effects of tizanidine, which is a… | 8 sources — open the full entry |
| Abiraterone Acetate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Acalabrutinib | Moderate | Absorption | INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its… | 2 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Adenosine | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide | Moderate | Synergy | Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents… | 18 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Aminophylline | Moderate | Metabolism | Cimetidine may increase theophylline plasma concentrations by as much as 70%. The mechanism is related to inhibition of liver CYP450 enzymes responsible for… | 30 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Amisulpride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy · Unknown | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…2 documented mechanisms | 39 sources — open the full entry |
| Apalutamide | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Arformoterol Tartrate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Aripiprazole | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Arsenic Trioxide | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…2 documented mechanisms | 42 sources — open the full entry |
| Asciminib | Moderate | Others | It is uncertain whether asciminib causes clinically significant prolongation of the QT interval of the electrocardiogram. | 2 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Atomoxetine Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumarate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Bicalutamide | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Brigatinib | Moderate | Synergy | Coadministration of brigatinib with other agents that can also slow the heart rate may potentiate the risk of severe bradycardia. | 2 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Synergy · Unknown | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…2 documented mechanisms | 39 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy · Unknown | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…2 documented mechanisms | 39 sources — open the full entry |
| Cefditoren | Moderate | Absorption | Coadministration with H2-receptor antagonists or other agents that reduce stomach acid (e.g., proton pump inhibitors) may decrease the oral absorption and… | 2 sources — open the full entry |
| Cefpodoxime Proxetil | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefpodoxime Proxetil + Clavulanic Acid | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefuroxime Axetil | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Cefuroxime Axetil + Clavulanic Acid | Moderate | Absorption | The coadministration with H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH may reduce the oral bioavailability of… | 4 sources — open the full entry |
| Ceritinib | Moderate | Absorption | Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been… | 2 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Chlorpromazine Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Cilostazol | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Synergy · Unknown | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…2 documented mechanisms | 39 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Citalopram Hydrobromide | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Clarithromycin | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafine | Moderate | Synergy · Unknown | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and…3 documented mechanisms | 39 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Clozapine | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
| Crizotinib | Moderate | Synergy | Famotidine may cause QTc prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and… | 39 sources — open the full entry |
Conditions
Conditions in which Famotidine needs care, as documented in this source.
Peptic Ulcer Hemorrhage
MajorHistamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.
5 sources
- "Product Information. Pepcid (famotidine)." Merck & Co., Inc (2002):
- "Product Information. Axid (nizatidine)." Lilly, Eli and Company (2002):
- "Product Information. Tagamet (cimetidine)." SmithKline Beecham (2001):
- "Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome (2001):
- "Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals (2002):
Kidney Diseases
ModerateFamotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous). The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients. Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients. Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient's clinical response.
7 sources
- Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR "Disposition of famotidine in renal insufficiency." J Clin Pharmacol 27 (1987): 782-7
- Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H "Pharmacokinetics and dynamics of famotidine in patients with renal failure." Br J Clin Pharmacol 26 (1988): 315-21
- Hachisu T, Yokoyama T, Oda Y, Ando K, Hattori Y, Yoshida T "Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure." Clin Ther 10 (1988): 656-63
- Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N, et al. "Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function." Eur J Clin Pharmacol 28 (1985): 327-31
- Kroemer H, Klotz U "Pharmacokinetics of famotidine in man." Int J Clin Pharmacol Ther Toxicol 25 (1987): 458-63
- "Product Information. Pepcid (famotidine)." Merck & Co., Inc (2002):
- Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
Therapeutic duplication
Drug classes that overlap with Famotidine, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Esomeprazole/naproxen
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Prevpac
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Amoxicillin/clarithromycin/omeprazole
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Voquezna triple pak
acid suppressant agents
The recommended maximum number of medicines in the 'acid suppressant agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'acid suppressant agents' category.
Example product in the source data (US market): Omeprazole/sodium bicarbonate